Arcellx (ACLX)
(Real Time Quote from BATS)
$54.25 USD
+0.63 (1.18%)
Updated May 20, 2024 09:59 AM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACLX 54.25 +0.63(1.18%)
Will ACLX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACLX
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
ACLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
Other News for ACLX
Arcellx price target raised by $1 at Stifel, here's why
Evercore says biotech ‘winter is finally thawing’
Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Analyst Expectations For Arcellx's Future
Buy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market Positioning